Serina Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
SER$1.430.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Six months ended June 30, | ||
|---|---|---|
| 2026 | 2025 | |
| OPERATING ACTIVITIES: | ||
| Net loss | $(13,254) | $(11,284) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 36 | 33 |
| Non-cash lease expense | 107 | 116 |
| Non-cash interest expense | 251 | — |
| Amortization of debt issuance costs | 141 | — |
| Stock-based compensation | 2,128 | 1,846 |
| Common stock issued to consultant for services rendered | — | 60 |
| Restricted stock units released to consultant for services rendered | — | 29 |
| Change in fair value of liability classified instruments | (1,531) | (33) |
| Loss on extinguishment of financial commitment assets and contingent warrants, net | 1,616 | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (664) | 50 |
| Accounts payable | (71) | 963 |
| Accrued expenses | 113 | (115) |
| Operating lease liabilities | (107) | (105) |
| Other current liabilities | (17) | 368 |
| Net cash used in operating activities | (11,252) | (8,072) |
| INVESTING ACTIVITIES: | ||
| Purchase of equipment | (53) | (46) |
| Net cash used in investing activities | (53) | (46) |
| FINANCING ACTIVITIES: | ||
| Proceeds from the exercise of stock options | 9 | 2 |
| Proceeds from Juvenescence stock purchase, net of issuance costs | — | 4,916 |
| Proceeds from issuance of Series A convertible preferred stock, net | — | 4,940 |
| Proceeds from issuance of common stock under at-the-market sales agreement, net | 10,169 | 629 |
| Proceeds from issuance of common stock and warrants in connection with private placement, net | 21,081 | — |
| Net cash provided by financing activities | 31,259 | 10,487 |
| Effect of foreign currency on cash | 14 | — |
| NET INCREASE IN CASH AND CASH EQUIVALENTS | 19,968 | 2,369 |
| CASH AND CASH EQUIVALENTS: | ||
| At beginning of the period | 3,056 | 3,672 |
| At end of the period | $23,024 | $6,041 |
| SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING AND INVESTING ACTIVITIES: | ||
| Transfer of right‑of‑use assets to property and equipment upon title transfer | $— | $75 |
| Initial recognition of Tranche Liability | $3,282 | $— |
| Settlement of Tranche Liability | $1,905 | $— |
| Deemed dividend on down round provision from Series A Convertible Preferred Stock | $2,539 | $— |
| Conversion of Preferred Series A stock into common stock | $4,940 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.